Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer (Q27853180)

From Wikidata
Jump to navigation Jump to search
scientific article published on 14 July 2015
edit
Language Label Description Also known as
English
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
scientific article published on 14 July 2015

    Statements

    Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer (English)
    P A Jänne
    0 references
    I Smith
    0 references
    G McWalter
    0 references
    H Mann
    0 references
    B Dougherty
    0 references
    J Walker
    0 references
    M C M Orr
    0 references
    D R Hodgson
    0 references
    A T Shaw
    0 references
    J R Pereira
    0 references
    G Jeannin
    0 references
    J Vansteenkiste
    0 references
    C H Barrios
    0 references
    F A Franke
    0 references
    L Crinò
    0 references
    P Smith
    0 references
    14 July 2015
    0 references
    113
    0 references
    2
    0 references
    199-203
    0 references

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit